We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $767M
1-Year Est. Return 119.71%
This Fund
S&P 500
This Quarter Est. Return
+6.27%
1 Year Est. Return
+119.71%
3 Year Est. Return
+244.81%
5 Year Est. Return
+382.5%
10 Year Est. Return
+2,655.81%
AUM
$1.02B
AUM Growth
-$45.6M
Cap. Flow
+$4.02M
Cap. Flow %
0.39%
Top 10 Hldgs %
45.69%
Holding
126
New
39
Increased
20
Reduced
28
Closed
30

Top Buys

Rank Stock Value
1
BTAI
BioXcel Therapeutics
BTAI
+$12.6M
2
JNJ icon
Johnson & Johnson
JNJ
+$11.8M
3
GNRC icon
Generac Holdings
GNRC
+$11M
4
TEVA icon
Teva Pharmaceutical Industries Limited
TEVA
+$10.6M
5
LLY icon
Eli Lilly
LLY
+$10.2M

Top Sells

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$41.2M
2
NVO
Novo Nordisk
NVO
+$26.2M
3
NICE icon
Nice
NICE
+$14.2M
4
FVRR icon
Fiverr
FVRR
+$11.8M
5
QTTB icon
Q32 Bio
QTTB
+$10M

Sector Composition

Rank Sector Weight
1 Healthcare 71.97%
2 Miscellaneous 15.76%
3 Technology 5.67%
4 Consumer Discretionary 2.57%
5 Industrials 2.19%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ADMA icon
76
ADMA Biologics
ADMA
$2B
$2.58M 0.25%
1,081,292
-903,657
-46% -$2.48M
LONA
77
LeonaBio Inc
LONA
$65.5M
$2.07M 0.2%
+11,200
New +$1.87M
ORGS
78
DELISTED
Orgenesis Inc. Common Stock
ORGS
$2.01M 0.2%
39,880
-26,697
-40% -$1.45M
ALPN
79
DELISTED
Alpine Immune Sciences Inc
ALPN
$1.74M 0.17%
+198,260
New +$1.81M
EPIX
80
DELISTED
ESSA Pharma
EPIX
$1.73M 0.17%
+250,000
New +$1.7M
CYPH
81
Cypherpunk Technologies Inc
CYPH
$331M
$1.58M 0.16%
80,000
-8,000
-9% -$154K
ETNB
82
DELISTED
89bio
ETNB
$1.51M 0.15%
+58,939
New +$1.87M
DYN icon
83
Dyne Therapeutics
DYN
$3.37B
$1.41M 0.14%
+70,000
New +$1.54M
XCUR icon
84
Exicure
XCUR
$8.84M
$1.29M 0.13%
4,917
-7,750
-61% -$2.53M
NBSE
85
DELISTED
NeuBase Therapeutics, Inc. Common Stock
NBSE
$1.14M 0.11%
7,500
– –
OBIO icon
86
Orchestra BioMed
OBIO
$347M
$1.1M 0.11%
+100,000
New +$1.12M
PAND
87
DELISTED
Pandion Therapeutics Inc. Common Stock
PAND
$1.09M 0.11%
+95,000
New +$1.62M
SEDG icon
88
SolarEdge
SEDG
$2.21B
$957K 0.09%
4,017
-42,000
-91% -$8.07M
NRIX icon
89
Nurix Therapeutics
NRIX
$2.65B
$785K 0.08%
+22,480
New +$567K
CRDF icon
90
Cardiff Oncology
CRDF
$101M
$568K 0.06%
+40,000
New +$264K
IMTXW
91
DELISTED
Immatics N.V. Warrants
IMTXW
$350K 0.03%
+100,000
New +$334K
PNT
92
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
$288K 0.03%
+20,000
New +$273K
CRBP icon
93
CALL
Corbus Pharmaceuticals
CRBP
$140M
$141K 0.01%
2,617
-5,333
-67% -$966K
CLRB icon
94
Cellectar Biosciences
CLRB
$22.7M
$109K 0.01%
292
– –
OTLKW
95
DELISTED
Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022
OTLKW
$17K ﹤0.01%
129,500
– –
AKBA icon
96
Akebia Therapeutics
AKBA
$248M
– –
-155,000
Closed -$2.1M
APRE icon
97
Aprea Therapeutics
APRE
$9.44M
– –
-7,914
Closed -$6.14M
BMY icon
98
Bristol-Myers Squibb
BMY
$128B
– –
-700,000
Closed -$41.2M
CAMT icon
99
Camtek
CAMT
$6.73B
– –
-37,184
Closed -$468K
CGEN icon
100
Compugen
CGEN
$233M
– –
-200,000
Closed -$3M
1 2 3
4
5

Similar funds

ISWM
Independent Solutions Wealth Management Williamsville, New York $766M AUM 31.53% 1-Year Est. Return
ACP
Albar Capital Partners London, United Kingdom $767M AUM 61.96% 1-Year Est. Return
NIM
Nexus Investment Management Toronto, Ontario, Canada $767M AUM 30.97% 1-Year Est. Return
ACM
Arvin Capital Management Austin, Texas $766M AUM 36.51% 1-Year Est. Return
CBT
Crews Bank & Trust Wauchula, Florida $766M AUM 19.5% 1-Year Est. Return
SPIA
Strategic Point Investment Advisors Providence, Rhode Island $767M AUM 17.58% 1-Year Est. Return
CNB
Camden National Bank Camden, Maine $767M AUM 14.32% 1-Year Est. Return
HI
Hendershot Investments Centreville, Virginia $766M AUM 10.81% 1-Year Est. Return

Sphera Funds Management's Q3 2020 Portfolio in Review

As of Q3 2020, Sphera Funds Management held 126 positions worth $1.02B, down 4.3% from $1.06B the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Sphera Funds Management's Q3 2020 filing shows 39 new, 20 increased, 28 reduced and 30 closed positions. Its largest new stake was BioXcel Therapeutics: 16,831 shares worth $11.7M. The largest sale was Bristol-Myers Squibb, an estimated $41.2M.

By sector, the portfolio is most concentrated in Healthcare at 72% of assets, up from 66% a quarter earlier, followed by Miscellaneous and Technology.

  • Sphera Funds Management's largest Q3 2020 buy was BioXcel Therapeutics: 16,831 shares worth $11.7M.
  • Sphera Funds Management added most to Johnson & Johnson in Q3 2020, an estimated $11.8M increase.
  • Sphera Funds Management's biggest Q3 2020 reduction was Nice, cutting an estimated $14.2M.
  • Sphera Funds Management fully exited Bristol-Myers Squibb in Q3 2020, selling an estimated $41.2M.
  • Sphera Funds Management's ten largest holdings make up 46% of its $1.02B portfolio in Q3 2020.
  • Sphera Funds Management opened 39 new positions and closed 30 in Q3 2020.
  • Sphera Funds Management's portfolio value fell 4.3% quarter-over-quarter to $1.02B.

Based on Sphera Funds Management's 13F filing for Q3 2020, filed 12 Nov 2020.